Vitamin C, VIP (vasoactive intestinal polypeptide) and gastrin in the serum of COPD patients in stable state and during exacerbation Source: Eur Respir J 2002; 20: Suppl. 38, 259s Year: 2002
VIP (vasoactive intestinal polypeptide) and vitamin C in the serum of COPD patients before and after therapy Source: Eur Respir J 2006; 28: Suppl. 50, 37s Year: 2006
Concentration of vasoactive intestinal peptide (VIP) and substance P (SP) in bronchi of patients with mild to moderate bronchial asthma Source: Eur Respir J 2005; 26: Suppl. 49, 583s Year: 2005
Vasoactive intestinal peptide receptors in the airways of smokers with chronic bronchitis Source: Eur Respir J 2004; 24: 958-963 Year: 2004
Vasoactive intestinal peptide-receptor regulation in monocytes derived from COPD patients Source: Annual Congress 2007 - Cell biology of asthma and COPD Year: 2007
Circulating vasoactive intestinal peptide for diagnosis of exacerbation of COPD Source: International Congress 2015 – Monitoring and phenotyping COPD Year: 2015
Vasoactive intestinal peptide receptor 2 (VIPR2) in central airways of smokers Source: Eur Respir J 2002; 20: Suppl. 38, 88s Year: 2002
Distribution of vasoactive intestinal peptide( VIP)- and substance P (SP)- containing innervation in bronchi of patients with bronchial asthma Source: Eur Respir J 2004; 24: Suppl. 48, 128s Year: 2004
Effects of different pacing modes on vasoactive intestinal peptide levels in pacemaker patients with chronic obstructive pulmonary disease Source: Eur Respir J 2001; 18: Suppl. 33, 58s Year: 2001
Vasoactive intestinal peptide (VIP) for treatment of COPD: improvement in spiroergometry and 6 minute walking distance Source: Eur Respir J 2006; 28: Suppl. 50, 430s Year: 2006
Vip in the serum of asthmatic patients and in COPD patients in stable state and during exacerbation Source: Eur Respir J 2007; 30: Suppl. 51, 403s Year: 2007
The effect of diuretics on plasma brain natriuretic peptide level in patients with acute exacerbations of chronic obstructive pulmonary disease Source: Annual Congress 2007 - Treatment of COPD Year: 2007
Inhaled vasoactive intestinal peptide (VIP) improves pulmonary gas exchange in acute respiratory distress syndrome (ARDS) - a case report Source: Eur Respir J 2003; 22: Suppl. 45, 70s Year: 2003
Effects of an acute exacerbation requiring hospitalisation (AE) on lung function, muscle force and serum IGF-I levels in male patients with chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2002; 20: Suppl. 38, 564s Year: 2002
Increased total serum levels of ghrelin and nesfatin in chronic obstructive pulmonary disease Source: International Congress 2015 – Notable abstracts in exacerbations, mechanisms and biomarkers in COPD Year: 2015
Brain natriuretic peptide (BNP) levels during acute exacerbations of COPD – a novel biomarker Source: Annual Congress 2008 - Mechanisms of respiratory infections: interaction between the pathogen and the host Year: 2008
Serum leptin levels in patients with chronic airway diseases Source: Eur Respir J 2005; 26: Suppl. 49, 306s Year: 2005
Presence of inspiratory crackles (IC) in stable chronic obstructive pulmonary disease (COPD) patients; correlation with plasma N-terminal pro-brain natriuretic peptide (NT-BNP) levels Source: Annual Congress 2008 - Assessment of the respiratory system Year: 2008
Effect of systemic steroid treatment on serum leptin levels in patients with COPD exacerbation Source: Eur Respir J 2005; 26: Suppl. 49, 284s Year: 2005
N-terminal-pro-B-type natriuretic peptide (NT-proBNP) in patient with acute exacerbations (AE) of COPD Source: Annual Congress 2008 - Biomarkers and disease assessment in COPD Year: 2008